Sugi Predict

Sugi Predict / Compounds / SCHEMBL4164142

SCHEMBL4164142

SCHEMBL4164142

c1cnc2c(c1)cnc1ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.66
▸ KDM4E B2RXH2 4/20 0.61
▸ GPR3 P46089 1/20 0.61
▸ CYP3A4 P08684 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.50
▸ ADORA3 P0DMS8 1/20 0.47
▸ CCR1 P32246 3/20 0.46
▸ CCR8 P51685 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HSP90AA1 P07900 2/20 0.46
▸ GMNN O75496 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ THPO P40225 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthridine SCHEMBL15913419 0.86 LMNA (0.74) LMNAKDM4EGPR3CYP3A4ALDH1A1
Phenanthridine SCHEMBL10802284 0.85 LMNA (0.72) LMNAKDM4EGPR3CYP3A4ALDH1A1
SCHEMBL3092457 0.84 KDM4E (0.61) LMNAKDM4EGPR3CYP3A4ALDH1A1
Hydrochloric Acid SCHEMBL28484677 0.82 KDM4E (0.59) LMNAKDM4EGPR3CYP3A4ALDH1A1
SCHEMBL28524695 0.82 LMNA (0.96) LMNAKDM4ECYP3A4ALDH1A1CCR1
SCHEMBL27885494 0.82 LMNA (0.96) LMNAKDM4ECYP3A4ALDH1A1CCR1
SCHEMBL18099778 0.81 CCR1 (0.58) LMNAKDM4EGPR3CYP3A4ALDH1A1
Quinoline SCHEMBL9104755 0.81 LMNA (0.85) LMNAKDM4ECYP3A4ALDH1A1CCR1
Phenazine SCHEMBL5691639 0.81 LMNA (0.85) LMNAKDM4EGPR3CYP3A4ALDH1A1
SCHEMBL6513577 0.79 LMNA (1.00) LMNAKDM4ECYP3A4ALDH1A1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119219650-A Benzo [1,6] naphthyridine derivative and medical application thereof 山东笑康生物科技有限公司 2024-12-31 — — CN claimed
US-8212048-B2 Method of producing aromatic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-03 — — US claimed
CN-120483979-A Method for synthesizing benzo [ H ] [1,6] naphthyridine-5 (6H) -ketone framework compound 桂林医科大学 2025-08-15 — — CN disclosed
CN-120483979-A Method for synthesizing benzo [ H ] [1,6] naphthyridine-5 (6H) -ketone framework compound 桂林医科大学 2025-08-15 — — CN disclosed
CN-119219650-B Benzo [1,6] naphthyridine derivative and medical application thereof 山东笑康生物科技有限公司 2025-06-06 — — CN disclosed
CN-119219650-B Benzo [1,6] naphthyridine derivative and medical application thereof 山东笑康生物科技有限公司 2025-06-06 — — CN disclosed
CN-119504749-A Aaptamine alkaloid and preparation method and application thereof 北京大学宁波海洋药物研究院 2025-02-25 — — CN disclosed
CN-119219650-A Benzo [1,6] naphthyridine derivative and medical application thereof 山东笑康生物科技有限公司 2024-12-31 — — CN disclosed
CN-119219650-A Benzo [1,6] naphthyridine derivative and medical application thereof 山东笑康生物科技有限公司 2024-12-31 — — CN disclosed
CN-119219650-A Benzo [1,6] naphthyridine derivative and medical application thereof 山东笑康生物科技有限公司 2024-12-31 — — CN disclosed
CN-118076602-A Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses 嘉兴优博生物技术有限公司 2024-05-24 — — CN disclosed
US-8212048-B2 Method of producing aromatic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-07-03 — — US disclosed
US-20090043096-A1 METHOD OF PRODUCING AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-12 — — US disclosed
US-7183010-B2 Organic light-emitting diode devices with improved operational stability EASTMAN KODAK CORPORATION (US) 2007-02-27 — — US disclosed
US-20050113455-A1 Method and composition for amelioration of pain UNIVERSITY OF FLORIDA 2005-05-26 — — US disclosed
WO-2005041988-A1 METHOD AND COMPOSITION FOR PAIN AMELIORATION UNIVERSITY OF FLORIDA (US) 2005-05-12 — — WO disclosed
EP-1436000-A2 TREATMENT OF NON-SOLID MAMMALIAN TUMORS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONISTS IMCLONE SYSTEMS, INC. (US) 2004-07-14 — — EP disclosed
US-20040076853-A1 Organic light-emitting diode devices with improved operational stability EASTMAN KODAK COMPANY 2004-04-22 — — US disclosed
WO-2001079205-A1 BENZO[H][1,6]NAPHTHYRIDINE AND AZEPINO[3,2C]QUINOLINE IMINO-ETHERS, PREPARATION METHOD AND THERAPEUTIC USE THEREOF UNIVERSITE DE CAEN BASSE-NORMANDIE (FR) 2001-10-25 — — WO disclosed
WO-2001074296-A2 TREATMENT OF NON-SOLID MAMMALIAN TUMORS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONISTS IMCLONE SYSTEMS INCORPORATED (US) 2001-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113455-A1 Method and composition for amelioration of pain SIGMAR1, ADORA2B, OPRL1 LMNA 1650/4885KDM4E 2646/4885GPR3 115/4885
US-20090043096-A1 METHOD OF PRODUCING AROMATIC COMPOUND AHR, CYP1A1, ARNT LMNA 2466/4885KDM4E 3177/4885GPR3 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.